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Abstract
Background: Fibroblast growth factor receptors (FGFRs) are well-known proto-oncogenes in several human
malignancies and are currently therapeutically targeted in clinical trials. Among glioma subtypes, activating FGFR1
alterations have been observed in a subpopulation of pilocytic astrocytomas while FGFR3 fusions occur in IDH
wild-type diffuse gliomas, resulting in high FGFR3 protein expression. The purpose of this study was to associate
FGFR1 and FGFR3 protein levels with clinical features and genetic alterations in ependymoma and pilocytic astrocytoma.
Methods: FGFR1 and FGFR3 expression levels were detected in ependymoma and pilocytic astrocytoma tissues using
immunohistochemistry. Selected cases were further analyzed using targeted sequencing.
Results: Expression of both FGFR1 and FGFR3 varied within all tumor types. In ependymomas, increased FGFR3 or
FGFR1 expression was associated with high tumor grade, cerebral location, young patient age, and poor prognosis.
Moderate-to-strong expression of FGFR1 and/or FGFR3 was observed in 76% of cerebral ependymomas. Cases with
moderate-to-strong expression of both proteins had poor clinical prognosis. In pilocytic astrocytomas,
moderate-to-strong FGFR3 expression was detected predominantly in non-pediatric patients. Targeted
sequencing of 12 tumors found no protein-altering mutations or fusions in FGFR1 or FGFR3.
Conclusions: Elevated FGFR3 and FGFR1 protein expression is common in aggressive ependymomas but
likely not driven by genetic alterations. Further studies are warranted to evaluate whether ependymoma
patients with high FGFR3 and/or FGFR1 expression could benefit from treatment with FGFR inhibitor based
therapeutic approaches currently under evaluation in clinical trials.
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Background
Fibroblast growth factor receptors (FGFRs) are a family
of receptor tyrosine kinases that are activated in a variety
of cancers and have well-established oncogenic properties
[1, 2]. Since the discovery of recurrent FGFR gene fusions
in glioblastoma [3, 4], FGFR inhibitor based treatment
regimens have been viewed as a promising therapeutic op-
tion for brain tumors with FGFR alterations. The mecha-
nisms of FGFR activation in brain tumors vary by tumor
type, but include oncogenic FGFR3 and FGFR1 fusions,
FGFR1 rearrangements, and FGFR1 mutations [2–8].
Moreover, gene fusions appear to be the sole recurrent
oncogenic FGFR3 alteration in brain tumors. Although
FGFR3 is commonly fused to a transforming acidic coiled-
coil-containing protein 3 (TACC3) gene, other fusion
partners exist. For example, recurrent FGFR3–BAIAP2L1
fusions have been detected in bladder cancer [9]. Several
FGFR inhibitors are currently under pre-clinical and
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clinical evaluation, and recent reports have shown good
treatment responses in FGFR3 fusion positive cells and
tumors [8, 10, 11]. While most of the FGFR inhibitor
studies, to date, have been performed in cases involving
carcinomas, responses to FGFR inhibitors have also been
reported in cases with glioblastoma [8, 12].
Ependymomas and pilocytic astrocytomas are nondif-
fuse gliomas, in which neoplastic cells do not substan-
tially infiltrate into surrounding normal tissue. They
represent different grades, types of growth and clinical
courses. Nondiffuse growth pattern facilitates efficient
surgical removal of the tumor, which partly explains the
better prognosis in these patients relative to those with
diffuse gliomas. However, tumor recurs in some of the
patients, and overall survival rates are worse with more
aggressive ependymomas [13].
Ependymomas are the third most common brain
tumor in children, representing 8–10% of pediatric intra-
cranial tumors and approximately 4% of all adult brain
tumors [13]. Ependymomas are found in all locations of
the central nervous system, and may be intracranial
(infratentorial or supratentorial) or spinal. Infratentorial
posterior fossa ependymomas can be further subclassi-
fied into posterior fossa group A (PFA) and group B
(PFB) tumors [14]. Adult ependymomas are typically
grade I myxopapillary ependymomas localized in the
spinal cord, while pediatric ependymomas are typically
intracranial grade II–III tumors [13, 15]. Although epen-
dymomas in young children are typically associated with
poor prognosis [15, 16], adult supratentorial ependymo-
mas are also associated with lower survival rates [13].
Apart from copy number alterations [13], significant
genetic and epigenetic drivers of ependymoma develop-
ment have been recently reported. C11orf95–RELA fu-
sions have been observed to occur in two-thirds of
pediatric cases of supratentorial ependymomas and are
believed to be oncogenic due to increased NF-kB signaling
[17]. Furthermore, a subtype of cerebellar ependymomas
that is associated with young patient age and poor prog-
nosis is characterized by a CpG island methylator pheno-
type (CIMP) and Polycomb repressive complex 2 driven
trimethylation of H3K27. These tumors are responsive to
pharmacological therapies targeting epigenetic regulators
[18]. The authors also highlighted the low rate of recur-
rent mutations and copy number alterations in cerebellar
ependymomas. Furthermore, FGFR alterations have not
been reported in high-throughput sequencing studies with
the exception of FGFR1 missense mutation N544 K [17]
localized to the tyrosine kinase domain of FGFR1.
Pilocytic astrocytoma (PA), the most common brain
neoplasm in the pediatric population, is classified as
WHO grade I [19, 20]. They arise most commonly in the
cerebellum, brainstem and the optic nerve. Familial PAs
are characterized by inactivation of the neurofibromatosis
1 (NF1) tumor suppressor gene, while activating BRAF
fusions and mutations are typical for sporadic PAs [19].
BRAF alterations subsequently lead to activation of the
MEK-ERK pathway [19], which is also an important
downstream signalling pathway for FGFR-induced sig-
naling [19, 21]. Additionally, FGFR1-TACC1 fusion has
been reported in a BRAF wild-type pilocytic astrocy-
toma of the diencephalon and several studies have
reported oncogenic structural FGFR1 variants with du-
plication of the tyrosine kinase domain [6, 7]. Further-
more, approximately 5% of PAs harbor an FGFR1
mutation targeting codons Asn546 or Lys656 in the
kinase domain [7]. The Lys656 mutation has been
associated with decreased patient survival [22]. Most
FGFR1-mutant tumors studied have been extra-
cerebellar, located mostly in midline locations, and mu-
tually exclusive with BRAF, NF1, and other recurrent
MAPK pathway alterations [7, 22]. Although these
studies did not report mutations or structural variants
in FGFR3, they emphasized the utility of FGFR1 as a
marker for PA subtyping.
In diffuse gliomas, FGFR3 protein level is an inform-
ative marker for fusion status [34]. Most tumors in a co-
hort of 791 cases did not have any detectable FGFR3
protein expression, and all the fusion-positive cases were
strongly stained (staining sensitivity 100% and specificity
88% in the targeted sequencing cohort). In non-diffuse
gliomas, FGFR1 alterations are commonly present in a
subgroup of pilocytic astrocytomas that lack other typ-
ical MAPK pathway alterations [6, 7], but FGFR1 and
FGFR3 expression levels have not been systematically
evaluated. Futhermore, FGFR fusions or increased FGFR
protein expression levels have not, to date, been re-
ported to occur in ependymomas. In the present study,
we sought to investigate the clinical significance of
FGFR3 and FGFR1 expression in two different nondif-
fuse gliomas: ependymomas and pilocytic astrocytomas.
We used immunohistochemistry to detect FGFR1 and
FGFR3 protein levels in ependymomas and pilocytic
astrocytomas, and evaluated the relationship between
protein expression levels, clinical features and selected
genetic alterations.
Methods
Patient samples
This study was approved by the Ethical Committee of
Tampere University Hospital and the National Au-
thority for Medico-legal Affairs in Finland. The study
cohort included 108 ependymal tumors from 88
patients, 97 pilocytic astrocytomas from 97 patients
(Table 1).
Ependymoma patients underwent neurosurgical oper-
ation with the intention of gross radical tumor resection
between 1984 and 2009 at Tampere University Hospital,
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between 1979 and 1998 at Kuopio University Hospital,
and between 1986 and 1999 at Turku University Hospital,
Finland. The clinical data detail about radicality of tumor
resection is imperfect, but radical resection has always
been performed when possible for the patient. Grade I
tumors included 17 myxopapillary ependymomas and
1 subependymoma. Grade II tumors included 68 epen-
dymomas, while Grade III tumors included 22 anaplas-
tic ependymomas, as classified according to WHO
criteria [23].
Pilocytic astrocytoma patients underwent tumor surgery
at the Tampere University Hospital between 1985 and
1999, at the Kuopio University Hospital between 1980 and
1992, at the Turku University Hospital between 1981 and
1992, and at the Helsinki University Hospital between
1986 and 1993.
Tissue histopathology and microarrays
Tumor samples were fixed in formaldehyde (buffered
with 4% phosphate) and embedded in paraffin. The
samples were processed into paraffin blocks and sections
were stained with hematoxylin and eosin (H&E). Histo-
pathological typing and grading, evaluation, and identifi-
cation of histologically representative tumor regions on
each slide were performed by an experienced neuro-
pathologist. Tissue microarray (TMA) blocks were
constructed using representative sample regions and a
custom-built instrument (Beecher Instruments, Silver
Spring, MD, USA). The diameter of the tissue core
on the microarray block was 0.6 or 1 mm, depending
on the TMA type. Five-micrometer-thick sections were
cut from representative array paraffin blocks.
Immunohistochemistry
Paraffin was removed with hexane. After rehydration in
ethanol, the pre-processing stage was performed using
Target Retrieval Solution citrate buffer (Dako). The sam-
ples were stained using rabbit monoclonal FGFR1 anti-
body (#9740, Cell Signaling Technology, 1:100 dilution)
and mouse monoclonal FGFR3 antibody (sc-13,121, Santa
Cruz Biotechnology, 1:600 dilution). ‘Envision + System-
horseradish peroxidase and diaminobenzidine (DAB)’ kit
(Dako) was used for FGFR3. The nuclei were stained
with hematoxylin. A mouse monoclonal antibody MIB-
1 (Ki-67 antigen, dilution 1:40, Immunotech, S.A.
Marseille, France) was used to analyze cell proliferation.
The tissue sections were counterstained with methyl
green. The percentage of tissue MIB-1-positive nuclei
was quantitatively evaluated using a computer-assisted
image analysis system (CAS-200 TM Software, Becton
Dickinson & Co., USA) and ImmunoRatio analysis.
Only neoplastic cells were included in the analysis
(necrotic and hemorrhagic areas were omitted).
The intensity of FGFR3 and FGFR1 immunoposi-
tivity was scored by two observers (HH and KG) on
a scale from 0 to 3 as follows: 0 (no staining), 1
(weak immunostaining), 2 (moderate immunostaining), or
3 (strong immunostaining).
Statistical analysis
All data were analyzed using R packages or IBM SPSS
statistics 21.0 software (SPSS Inc., Chicago, IL, USA) for
Windows. Tests for pairwise association between
discrete variables were performed using Fisher’s exact
test for count data. For tables larger than 2 × 2, the
p-values of Fisher’s exact tests were calculated using
Monte Carlo simulation with 2.5*10^7 replicates.
p-values were not corrected for multiple testing. Log-
Table 1 Patient demographics and clinical characteristics within
ependymoma and pilocytic astrocytoma tumor patient cohorts
Ependymomas Pilocytic
astrocytomas
Patients 88 80
Male 48 42
Female 40 38
Age (years)
Median (Mean ± SD) 37 (35 ± 21) 9 (14 ± 14)
Minimum 1 0
Maximum 73 58
Follow-up for primary tumor patients
Survivors in the end of the
follow-up
60 69
Follow-up time for survivors
(m) (median (mean ± SD))
125 (135 ± 82) 70 (111 ± 89)
5-year residive-free survival (%) 71 82
5-year survival (%) 82 93
Tumors 108 80
Primary 74 73
Second 14 5
Third 14 1
Fourth-sixth 6 1
Histological grade
I 18 80
II 68 0
III 22 0
Topography
Supratentorial 35 3
Infratentorial 28 69
Spinal 43 2
Cranial nerve 0 6
Patient age and follow-up information were calculated using primary cases.
Follow-up times are shown in months (m)
SD standard deviation
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rank test was used for the analysis of prognostic factors.
In cox regression analysis, cox model was built using a
stepwise forward likehood-ratio testing.
Targeted sequencing
All the tissue samples were formalin fixed and paraffin
embedded (FFPE). A turXTRAC FFPE DNA kit
(Covaris) or AllPrep DNA/RNA Mini Kit (Qiagen) was
used for DNA isolation. We used 1 μg of extracted
DNA for targeted sequencing using the Sureselect XT
Target enrichment system together with custom-
designed RNA probes (Additional file 1: Table S1).
The sequencing library was prepared according to the
kit instructions (200 ng of DNA samples) with a
shorter DNA-shearing protocol (220 s) and sequenced
with MiSeq (Illumina). Tumors Epe002 and Epe003
were derived from the first and the third tumor surgery
(after second recurrence) of one patient. In addition, the tu-
mors Epe004 (1st tumor surgery) and Epe005 (2nd tumor
surgery) were derived from a separate ependymoma
patient.
The resulting data were aligned against the GRCh37
human reference genome using Bowtie 2.2.4 [24]. Muta-
tions were identified in tumor samples by searching for
sites with an alternate allele fraction of at least 10%, and
at least 5 reads with the mutation. Additionally, the al-
lele fraction was required to be 20 times higher than the
background error rate (i.e., the average allele fraction
across control blood samples from healthy patients).
Protein-level consequences of variants were predicted
using ANNOVAR software tool [25]. Mutations with a
known or suspected pathological function were identi-
fied manually. To discover chromosomal rearrangements
for fusion detection, unaligned reads from each sample
were split into two 30 bp anchors (one from both ends)
that were aligned to the hg38 genome using Bowtie-
1.1.2. Discordant anchor pairs were grouped by position,
and groups with 8 or more supporting reads were
flagged as rearrangement candidates and manually cu-
rated using IGV and BLAT.
Log ratios of amplicon read counts were used for
DNA copy number calling. Differences in average cover-
age between samples were corrected on the basis of con-
trol amplicons in chromosomes 5, 8, 11, and 18 (14–21
amplicons per chromosome), positioned in regions with
the lowest rate of reported copy number alterations.
Blood-derived DNA from healthy individuals was used as
a negative control for the copy number analysis.
Results
We used an antibody that targets amino acids 25–124 in
the FGFR3 N-terminus to perform immunohistochemi-
cal (IHC) staining on 188 cases including ependymomas
or pilocytic astrocytomas (Table 1). FGFR3 staining was
localized to the cytoplasm and plasma membrane
(Fig. 1). Staining was typically heterogeneous in all
tumor types studied. Negatively stained blood vessels
provided an internal control for antibody specificity.
Normal brain tissue was immunonegative, with the
exception of the cerebellar and cerebral molecular
layers, where weak-to-moderate staining was observed
(Additional file 1: Figure S1a).
In ependymomas, FGFR3 staining is associated with
disease aggressiveness
Immunohistochemistry was used to investigate FGFR3
expression levels in 108 ependymal tumor samples ap-
plied to TMAs. The TMA cohort (Table 1), representing
different grades of ependymomas and disease subtypes,
has been partly reported previously [26]. FGFR3 immu-
noreactivity was detected in 27 (37%) of the cases; 11
(15%) showed weak immunostaining, 11 (15%) showed
moderate immunostaining and 5 (7%) were strongly
immunopositive. Increased staining was also observed in
pseudorosette structures (Additional file 1: Figure S1b).
Recurrent tumors showed typically similar staining levels
as the primary tumor. With respect to the association
analysis (Additional file 1: Figure S2), FGFR3 staining
was significantly associated with a higher tumor grade
(p < 0.01, Fisher’s exact test, Fig. 1b, Table 2). None of
the grade I cases showed detectable FGFR3 expression.
Moderate-to-strong FGFR3 immunostaining was pre-
dominantly detected in cerebral tumors as compared to
other locations (p < 0.001, Fisher’s exact test, Fig. 1c,
Table 2). Elevated FGFR3 immunopositivity in high-
grade cerebral tumors suggests that FGFR3 immuno-
staining may be typical for pediatric ependymomas.
Indeed, patients with age < 20 years at tumor onset had
a higher frequency of FGFR3 immunopositive staining
(p < 0.05, Fisher’s exact test, Fig. 1d). Cases with
moderate-to-strong FGFR3 immunostaining tend to
show a high proliferation rate (Fig. 1e), although this
association was not statistically significant (p = 0.07,
Fisher’s exact test). Importantly, moderate-to-strong
FGFR3 immunostaining was significantly associated with
shorter overall patient survival (p < 0.05, log-rank test,
Fig. 1f ) and shorter time to tumor recurrence (p < 0.01,
log-rank test, Fig. 1g). The association with disease-free
survival remained significant after adjustment for tumor
location, grade, and proliferation (p = 0.003, RR = 1.82,
95% CI 1.23–2.68 for FGFR3, other variables not significant
in the final equation, N = 77, stepwise Cox regression), but
only tumor location (p = 0.022, RR = 2.47, 95% CI 1.42–
5.34, N = 77, stepwise Cox regression) was a significant
prognostic predictor for disease-specific survival in multi-
factorial analysis. It is relevant to note the patient numbers
(N = 77) are rather low for multifactorial analysis using four
different variables. Still, the obtained results suggest that
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Fig. 1 Moderate-to-strong FGFR3 immunostaining was predictive of poor patient survival in ependymomas. a Representative staining images.
b Distribution of FGFR3 immunostaining in grade I–III ependymomas. FGFR3 immunostaining was positively associated with tumor grade (p < 0.01, Fisher’s
exact test). c Moderate-to-strong FGFR3 immunostaining was associated with cerebral tumor location (p < 0.0001, Fisher’s exact test). Total number of
tumors for each location is marked into the figure. d Moderate-to-strong FGFR3 expression was more common in younger patients (p < 0.05, Fisher’s exact
test). Only newly-diagnosed cases were included in the analysis and these were divided into those with negative-to-weak vs. moderate-to-strong FGFR3
immunostaining. e Cases with moderate-to-strong FGFR3 expression tended to have higher proliferation index (p = 0.07, Fisher’s exact test). Samples were
divided based on FGFR3 staining and proliferation rate (1: low, 2: intermediate, and 3: high proliferation index). f-g Moderate-to-strong FGFR3
immunostaining was associated with worse g) disease-specific survival (N = 73, p < 0.05, log-rank test) and g) recurrence-free survival (N = 70,
p < 0.01, log-rank test). Only newly-diagnosed cases were included into the analysis
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FGFR3 immunopositivity is associated with more aggressive
ependymomas.
As pediatric and adult ependymomas differ in many
respects and the age association might influence the ob-
served associations, we analyzed the pediatric and adult
sample cohorts independently. Patients that were at least
16 years old were considered as adults according to gen-
eral practice in Finnish pediatric clinics. There were 35
pediatric and 73 adult samples in our cohort. Moderate-
to-strong FGFR3 staining was slightly more common in
pediatric than adult samples (34.3% vs 13.7%, p = 0.055,
Fisher’s exact test, Table 2). In pediatric patients, moder-
ate FGFR3 immunostaining was observed in cerebellar
(31%, n = 16) and cerebral (29%, n = 14) tumors and
strong FGFR3 staining only in cerebral tumors (21%,
n = 14), whereas all the spinal cases (n = 5) were nega-
tive for FGFR3 (p = 0.065, Fisher’s exact test). FGFR3
staining was not associated with tumor grade or prolifer-
ation index in pediatric ependymomas. In adults, FGFR3
associations were largely very similar as in the whole
sample cohort: stronger FGFR3 staining was associated
with tumor grade (p < 0.01, n = 73, Fisher’s exact test),
tumor location (p < 0.001, n = 71, Fisher’s exact test)
and there was a close-to-significant association with pro-
liferation index (p = 0.095, n = 66, Fisher’s exact test).
Prognostic associations were mostly nonsignificant in
separate survival analyses in pediatric (n = 14) and adult
(n = 30) sample cohorts, but this was likely due to low
sample count in the analysis, as the trend remain the simi-
lar. Of note, when FGFR3 staining was divided into four
groups, it was associated with worse disease-specific
(p < 0.01, log-rank test) and disease-free (p < 0.001, log-
rank test) survival in pediatric patients.
FGFR1 staining is associated with higher tumor grade and
cerebral location
The interpretation of the FGFR1 immunostaining data
was not as straightforward as FGFR3 staining, partly be-
cause macrophages, neurons, and necrotic areas showed
immunopositive staining. Therefore, FGFR1 immunohis-
tochemical scoring was based on the presence of
FGFR1-positive malignant cell clusters or larger tumor
areas (i.e. diffuse staining), and scoring of individual cells
was omitted in the analysis. Sporadic moderate-to-
strong FGFR1 immunopositivity was also detected and
characterized by high outlier expression in individual
malignant cells. These observations support those from
previous reports [27]. FGFR1 staining was detected in
the cytoplasm and membrane compartments, while
granular staining was also observed in a subpopulation
of positively-stained samples. Interestingly, moderate-to-
strong FGFR1 immunostaining was also observed in
ependymal rosettes (Additional file 1: Figure S3).
Diffuse FGFR1 immunoreactivity was detected in 42
(58%) of ependymal tumors. Twenty-four cases (33%)
showed weak immunostaining, 15 (21%) cases showed
moderate immunoreactivity, and 3 (4%) cases showed
strong immunopositivity (Fig. 2a). Consistent with
FGFR3 expression, FGFR1 immunostaining was signifi-
cantly associated with a higher tumor grade (p < 0.05,
Fisher’s exact test, Fig. 2b, Table 2) and cerebral location
(p < 0.01, Fisher’s exact test, Fig. 2c, Table 2). Diffuse
FGFR1 staining was not significantly associated with
overall or recurrence-free survival but cases with high
FGFR1 expression had a tendency toward decreased sur-
vival rates in this cohort (Additional file 1: Figure S4).
When ependymomas were divided into pediatric (n = 34)
and adult (n = 72) patients, no associations were observed
for FGFR1 in the pediatric cohort. However, FGFR1
staining was similarly associated with tumor location
(p < 0.001, n = 70, Fisher’s exact test) and higher
tumor grade (p < 0.01, n = 72, Fisher’s exact test) in
the adult cohort as in the whole sample cohort. Fur-
thermore, a weak association was observed between
stronger FGFR1 staining and higher tumor proliferation
index (p = 0.061, n = 68, Fisher’s exact test) among adult
patients.
FGFR1 and/or FGFR3 levels are elevated in majority of the
cerebral ependymomas
Among ependymomas, marked (moderate-to-strong)
immunostaining for FGFR1, FGFR3, or both proteins oc-
curred more frequently in cerebral than in non-cerebral
tumors (76, 32, and 19% in cerebral, cerebellar, and spinal
tumors, respectively, p < 0.001, Fisher’s exact test, Fig. 2d).
Table 2 Samples numbers in FGFR1 low, FGFR1 high, FGFR3
low, and FGFR3 high groups in respect to tumor location,
tumor grade and patient age
FGFR1 low FGFR1 high FGFR3 low FGFR3 high
Tumor location
Spinal 37 6 41 2
Cerebellar 21 4 23 5
Cerebral 16 20 20 15
p-value 0.0001 0.0002
Tumor grade
I 16 2 18 0
II 50 15 54 14
III 10 13 14 8
p-value 0.002 0.013
Patient age
< 16 22 12 23 12
> =16 50 18 61 10
p-value 0.15 0.055
p-values have been calculated using Fisher’s exact test. High: Moderate-to-strong
immunostaining, Low: Negative-to-low immunostaining
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Fig. 2 Moderate-to-strong FGFR1 and/or FGFR3 expression is characteristic of aggressive ependymomas. a Representative images for FGFR1
staining in ependymomas. b The distribution of FGFR1 immunostaining in grade I-III ependymomas. FGFR1 staining was associated with higher
tumor grade (p < 0.05, Fisher’s exact test). c Moderate-to-strong FGFR1 immunostaining was associated with cerebral tumor location (p < 0.01,
Fisher’s exact test). Total number of tumors for each location is marked into the figure. d Moderate-to-strong immunostaining of FGFR1 and/or
FGFR3 was detected in a majority of cerebral ependymoma samples (p < 0.0001, Fisher’s exact test). e-f). Moderate-to-strong immunostaining of
both FGFR3 and FGFR1 was associated with e) poor disease-specific survival (N = 69, p < 0.05, log-rank test) and f worse recurrence-free survival
(N = 66, p < 0.05, log-rank test). Newly diagnosed cases were divided into four categories based on the expression of both FGFR1 and FGFR3.
High: Moderate-to-strong immunostaining, Low: Negative-to-low immunostaining
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Increased FGFR1 and/or FGFR3 expression was therefore
a common characteristic of cerebral tumors. Strikingly,
tumor tissues expressing marked (moderate-to-strong)
levels of both FGFR1 and FGFR3 were associated with sig-
nificantly worse patient survival than tissues obtained
from other cases, in terms of both overall mortality
(p < 0.05, log-rank test, Fig. 2e) and recurrence-free sur-
vival (p < 0.05, log-rank test, Fig. 2f). Furthermore, the
combined variable for FGFR1 and FGFR3 (both are
negative-to weak, either staining is moderate-to-strong or
both are moderate-to-strong) was the only significant pre-
dictor for the disease-specific survival (p = 0.014, RR = 1.91,
95% CI 1.14–3.20, N = 77, stepwise Cox regression) and
disease-free survival (p = 0.007, RR = 1.75, 95% CI 1.17–
2.62, N = 77, stepwise Cox regression), when it was com-
bined together with tumor location, grade, and prolifera-
tion index as explanatory factors in the multifactorial
analysis. It is good to remember that the patient numbers
(N = 77) are rather low for multifactorial analysis using
four different variables when interpreting these results.
Still, the obtained results support the aggressive nature of
tumors with moderate-to-strong staining of both FGFR1
and FGFR3. Our results are also concordant with previous
notions (e.g. [28]) that supratentorial and infratentorial
ependymomas are largely different and appear to repre-
sent distinct tumor entities.
FGFR3 staining is associated with increased patient age in
pilocytic astrocytoma
In the pilocytic astrocytoma cohort, 60 (82%) samples
were negative for FGFR3 expression, while only 21 cases
(22%) failed to show any FGFR1 expression (Fig. 3c-d).
Among samples with FGFR3 immunoreactivity, 7 sam-
ples (9%) showed weak immunostaining, 5 samples (6%)
showed moderate immunostaining, and 2 samples (3%)
were strongly immunopositive. Immunopositive FGFR3
staining was detected in both microcystic and pilocytic
areas. Among samples with positive FGFR1 staining, 59
samples (61%) showed weak immunopositivity, 16 sam-
ples (16%) samples showed moderate immunopositivity,
and 1 sample (1%) was strongly immunopositive.
Moderate-to-strong FGFR1 immunostaining was de-
tected predominantly in microcystic areas. Clinical asso-
ciation analysis (Additional file 1: Figure S5) did not
reveal any significant associations between FGFR1
staining and other clinical factors. Interestingly,
moderate-to-strong FGFR3 protein levels were associ-
ated with increased patient age (≥16 years, p < 0.01,
Fisher’s exact test, Fig. 3e). All but one of the six pri-
mary cases showing moderate-to-strong FGFR3 im-
munostaining were from patients who were at least
15 years old. FGFR3 immunostaining was not associ-
ated with tumor location or aneuploidy.
Absence of FGFR1 or FGFR3 fusions in targeted
sequencing cohort
Ten tumors showing moderate-to-strong FGFR1 or FGFR3
immunostaining were selected for targeted sequencing
analysis. All analyzed ependymomas were supratentorial.
In addition to FGFR3 and FGFR1, the sequencing panel in-
corporated genes with reported alterations in gliomas, in-
cluding IDH1, IDH2, TP53, ATRX, CIC, CDKN2A, RB1,
RELA, and BRAF (Additional file 1: Table S1). We did not
detect FGFR coding mutations or fusions in any of the
samples (Fig. 4, Additional file 2: Table S2, Additional
file 1: Figure S6). FGFR3 fusions were detected with
high sensitivity from large diffuse glioma cohort using
the same sequencing panel and methodology [34], sug-
gesting that the lack of detectable FGFR fusions was
not due to methodological limitations. The tumors se-
lected for analysis contained many known alterations, in-
cluding a C11orf95-RELA fusion and CDKN2A alterations
in ependymoma tumors (Epe001, Epe002 and Epe003).
RELA fusions and loss of CDKN2A have been routinely
observed in aggressive ependymomas [17, 29, 30]. ATERT
promoter mutation was observed in tumors Epe004 and
Epe005 obtained from the same ependymoma patient. In
addition, one pilocytic astrocytoma tumor harbored the
KIAA1549-BRAF fusion, which is the most frequent
MAPK pathway alteration in this tumor type [7]. It is in-
teresting that majority of sequenced PA samples did not
carry any BRAF or FGFR1 alterations, but limited sample
size does not allow full generalization of this result. A total
of 4 cases in our cohort did not carry any alterations in
targeted genes. This may be due, in part, to the fact that
all genomic regions were not covered during targeted se-
quencing. In addition, pilocytic astrocytomas are known
to harbor very few alterations [7].
Discussion
Our results demonstrate that moderate-to-strong FGFR3
and/or FGFR1 immunostaining was detectable in most
of the supratentorial ependymomas. In ependymoma,
moderate-to-strong FGFR3 staining was associated with
tumor location, higher proliferation index, and higher
grade. Similar associations were obtained when only
adult patients were included into the analysis. Moderate-
to-strong FGFR3 staining was more frequently observed
among pediatric patients than among adults, but only
the association between FGFR3 and tumor location
remained significant in the pediatric cohort. This might
be partly due to a small number of pediatric cases
(n = 35) and shortage of grade I tumors (n = 1) among
children. In any case, the data suggest that clinical asso-
ciations for FGFR3 were not solely due to age-related
differences. The situation was similar for FGFR1:
moderate-to-strong staining was associated with tumor
location and higher grade in both the whole and the
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adult cohort, despite the lack of clinical associations in
the pediatric cohort.
Tumors with high expression of both FGFR3 and
FGFR1 were associated with poor clinical prognosis in
ependymoma, suggesting that aggressive supratentorial
ependymomas may benefit from treatment regimens
based on FGFR inhibition. Additional work is required
to elucidate the significance of high FGFR1 and/or
FGFR3 expression as independent prognostic factors for
treatment response. The absence of FGFR alterations in
these tumors does not rule out the possibility of treat-
ment response. In head and neck squamous cell cancers
and various lung cancers, FGFR1 expression has, in fact,
been shown to predict treatment responses better than
0 20 40 60 80 100
FGFR1
FGFR3
negative weak moderate strong
% of cases
0 20 40 60 80 100
negative weak moderate strong
% of cases
16 years
<16 years
FGFR3
FGFR1 FGFR3
PositiveNegative PositiveNegative
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b) c)
N=22
N=54
n=80
n=97
Fig. 3 FGFR3 and FGFR1 staining in pilocytic astrocytoma. a Representative immunohistochemical images in pilocytic astrocytoma. b Distribution
of immunohistochemistry scores. The majority of samples were negative for FGFR3. c Nearly all of the pilocytic astrocytoma samples showing
moderate-to-strong FGFR3 immunostaining were obtained from non-pediatric patients (p < 0.01, Fisher’s exact test). Only newly-diagnosed tumors
were included into this analysis
Fig. 4 Summary of genetic alterations in the cases that were analyzed using targeted sequencing. No coding mutations or gene fusions were
detected in FGFR3 or FGFR1. FGFR1 and FGFR3 immunohistochemical staining scores are shown above the figure. If stained whole-mount tissue
slides were available, they were used for scoring. Pilocytic: pilocytic astrocytoma
Lehtinen et al. BMC Cancer  (2017) 17:310 Page 9 of 12
genomic alterations in FGFR1 [31, 32]. The location of
ependymal tumors may also permit drug delivery directly
via the cerebrospinal fluid, which would make the treat-
ment less systemic. Many traditional FGFR inhibitors
target also other growth factor receptors, such as
VEGFR and PDGFR [10], which might also be benefi-
cial. For example, Sie et al. [33] have shown that low
grade astrocytoma and ependymoma cell viability de-
creased upon the single use of one inhibitor on VEGF,
EGF, HGF, FGF and PDGF in vitro. On the other hand,
the recently developed FGFR-specific inhibitors have
generated responses in patients carrying FGFR alter-
ations and are typically associated with less toxic side
effects [12], which makes them a favorable treatment
option for these patients.
In pilocytic astrocytoma, moderate-to-strong FGFR3
staining was mostly observed in adult patients, which is
opposite to the trend in ependymoma, where moderate-
to-strong FGFR3 staining was more frequent in pediatric
cases. This further suggests that higher FGFR3 expres-
sion is not directly linked to young patient age or
pediatric tumor type.
In the present study, we did not detect any FGFR fusions
or coding mutations in the targeted sequencing cohort. An
FGFR1 Lys656 mutation has been reported to occur in the
absence of detectable FGFR1 expression in PA [22], sug-
gesting that immunohistochemical data may serve as a
valuable prognostic marker when FGFR inhibition is con-
sidered as a therapeutic option. FGFR1 is recurrently al-
tered in PA but only in a minority of cases, and, to date, the
presence of FGFR1 Lys656 mutation has not been shown
to correlate with FGFR1 staining intensity [22]. Intracranial
FGFR3 gene fusions have been only detected in IDH wild-
type diffuse gliomas [4, 6, 8, 34], suggesting that FGFR3 fu-
sions may contribute to the characteristics of this highly ag-
gressive and invasive type of glioma. We have previously
reported that FGFR3 fusion-positive cells were highly inva-
sive and predictive of poor prognosis in a xenograft model
[3]. Although FGFR1 fusions are rare in glioma, one fusion-
positive pediatric pilocytic/pilomyxoid astrocytoma case
has been previously reported [6], suggesting that FGFR1-
fusions are not restricted to diffuse gliomas. Moreover, vari-
ous FGFR1 alterations have been observed in pilocytic as-
trocytomas [6, 7], suggesting that genetic FGFR1 alterations
do not necessarily drive the development or progression of
highly malignant tumors.
Despite the high structural similarity between endogen-
ous FGFR1 and FGFR3, these results indicate that func-
tional differences may exist between the altered proteins.
Although the clinical associations of FGFR1 and FGFR3
immunostaining showed striking similarities, associations
between protein expression and patient survival were sig-
nificant only for FGFR3. These observations may be re-
lated to the relatively small cohort size (approximately 70
primary cases) involved in the present study. The difficulty
in interpreting FGFR1 immunostaining, combined with
the lack of a significant survival association in our cohort,
suggests that FGFR1 staining may not be as useful for
patient stratification as FGFR3.
Majority of cases did not show any detectable FGFR3
in both tumor types, which is consistent with our previous
results [34]. However, the proportion of patients with
moderate-to-strong FGFR3 immunostaining was higher in
ependymoma when compared to the diffuse astrocytoma
patient cohort (5%, [34] or pilocytic astrocytoma (9%).
Since FGFR3 fusions were not detected in any tumors in
this study, increased FGFR3 levels are likely to be caused
by differences in the trans-acting regulation of protein
expression.
Conclusions
Fibroblast growth factors are well-known oncogenes, which
have also been targeted in clinical trials. This study reports
variable FGFR1 and FGFR3 protein levels in ependymoma
and pilocytic astrocytoma. In ependymoma, moderate-to-
strong expression of FGFR3 was associated with cerebral
location, young patient age and poor prognosis. Ependy-
moma cases that co-expressed moderate-to-strong levels of
both FGFR3 and FGFR1 had significantly lower survival
rates. In pilocytic astrocytoma, moderate-to-strong FGFR3
staining was observed predominantly in non-pediatric
patients. Targeted sequencing analysis did not detect any
coding alterations in FGFR1 or FGFR3 genes in staining-
positive cases. This is different in diffuse gliomas, were
strong FGFR3 staining can be used to indicate the pres-
ence of FGFR3 fusion. However, FGFR inhibition might
be a suitable treatment option for ependymomas with
moderate-to-strong FGFR3 or FGFR3 + FGFR1 expres-
sion, as these patients had poor prognosis and we are
currently lacking efficient regimens for their treatment.
Additional files
Additional file 1: Supplementary Material. Description of data: Table S1.
Target regions for probe design for targeted sequencing. Coordinates were
extracted using genome assembly GRCh37/hg19. Figure S1. Representative
staining images. a) Weak-to-moderate FGFR3 staining was observed in
cerebellar molecular layer (100× magnification). b) FGFR3 staining in
pseudorosette structures in ependymoma (200× magnification). Figure S2.
Association analyses in the ependymoma cohort including all the cases. p-
values were calculated using Fisher’s exact test. Figure S3. Moderate-to-strong
FGFR1 staining in ependymal rosettes. Figure S4. Survival association analysis
for FGFR1 staining in the ependymoma cohort was not statistically significant.
a) Overall survival, b) Recurrence-free survival. Newly diagnosed cases were
divided into two categories: low (negative-to-weak) or high (moderate-to-
strong) FGFR1 staining. Figure S5. Association analyses in the pilocytic
astrocytoma cohort including all the cases. p-values were calculated using
Fisher’s exact test. Figure S6. Alignment and coverage statistics of the
targeted sequencing cohort. (a) Total reads, grouped by alignment result. (b)
Number of duplicate reads among all aligned reads. (c) Violin plot showing
coverage distribution across all bases in target regions. (PDF 6130 kb)
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